Inhibikase Therapeutics, INC. 8-K Filing
Ticker: IKT · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1750149
Sentiment: neutral
Filing Stats: 627 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2025-12-19 16:17:43
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
- $185,000,000 — ng an aggregate offering price of up to $185,000,000, from time to time, through Jefferies L
Filing Documents
- d212017d8k.htm (8-K) — 28KB
- d212017dex51.htm (EX-5.1) — 7KB
- 0001193125-25-326916.txt ( ) — 153KB
- ikt-20251219.xsd (EX-101.SCH) — 3KB
- ikt-20251219_lab.xml (EX-101.LAB) — 18KB
- ikt-20251219_pre.xml (EX-101.PRE) — 11KB
- d212017d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Number Description 1.1 Open Market Sale Agreement SM , dated June 20, 2025, by and between Inhibikase Therapeutics, Inc. and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 filed by the Registrant on June 20, 2025). 5.1* Opinion of Goodwin Procter LLP. 23.1* Consent of Goodwin Procter LLP (included in Exhibit 5.1). 104* Cover Page Interactive Data File (embedded within the Inline XBRL document). * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2025 INHIBIKASE THERAPEUTICS, INC. By: /s/ Mark Iwicki Mark Iwicki Chief Executive Officer